this study explored the effects of gnrh agonist (gnrha) immunity on expression of fshr mrna in pituitary and fshr protein in uteri, and also confirmed its efficacy on uterine development. 42 prepuberty and non cyclic ewes were assigned to 6 experimental groups (eg) during anestrus season. animals in eg-i, eg-ii and eg-iii were subcutaneously injected with 200, 300 and 400 μg alarelin antigens (...

results from 110 subjects with cpp, 46 girls (41.8%) were considered as intervention and 64 (58.2%) as control groups. the mean age at initial visit was 7.46 ± 1.03 years. the bmi standard deviation scores in both groups was not significantly different at sixth and 12th months of treatment compared with baseline (p = 0.257 and p = 0.839, respectively). the prevalence of obesity was not signific...

Long-acting synthetic luteinising hormone-releasing hormone agonists have become the mainstay for androgen-deprivation therapy, because they avoid the physical and psychological discomfort associated with orchidectomy and lack the potential cardiotoxicity associated with estrogens such as diethylstilbestrol. Currently available luteinising hormone-releasing hormone agonist analogues include leu...

Background: The long protocol has been recognized as the gold standard in controlled ovarian hyperstimulation (COH). However, full dose of gonadotropin-releasing hormone agonist (GnRH-a) under prolonged become increasingly popular China. This study sought to compare pregnancy outcomes among following 3 groups: a group, and 2 types improved groups.

To assess the effects of a gonadotropin-releasing hormone agonist, [D-Leu6,des-Gly10] luteinizing hormone-releasing hormone ethylamide, in ameliorating the damage caused by ionizing radiation, gonadotropin-releasing hormone agonist was administered to rats from day 22 to 37 of age in doses of 0.1, 0.4, and 1.0 microgram/day or vehicle and the rats were sacrificed on day 44 of age. There were no...

background: gonadotrophin-releasing hormone (gnrh) agonist is used for controlling ovarian stimulation in assisted reproductive technology (art) cycles which has some benefits. objective: to compare the efficacy of two different formulations of gnrh agonist: short-acting and long-acting, for art protocols. materials and methods: in a prospective randomized study, one hundred women who underwent...

OBJECTIVE: The aim of this study is to evaluate the outcomes gonadotropin-releasing hormone agonist treatment for ovarian cysts, which are developed during tamoxifen use due breast cancer. STUDY DESIGN: This was a retrospective cohort including patients who were under stage I-III cancer and administered leuprolide acetate cysts with low malignancy risk between 2012-2020. RESULTS: Leuprolide tot...